Clinical Trial: Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439887) titled 'Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease' on Feb. 18.

Brief Summary: A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 in the study eye and be followed for 5 years.

Study Start Date: Jan. 28

Study Type: INTERVENTIONAL

Condition: Stargardt Disease

Intervention: GENETIC: RTx-021

Optog...